ERBB2 and breast carcinoma: For adjuvant systemic therapy in patients with non-metastatic, ER/PR positive, HER2 negative, and N0-1 breast cancers, the 70-gene MMP test is recommended as evidence of category 1 in the 2022 NCCN guidelines [9].